Keywords: Abscopal effect; mCRPC; Positron emission tomography; Prostate-specific membrane antigen; Radium-223;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ARSIs; androgen receptor signaling inhibitors; AA; abiraterone acetate; AR; androgen receptor; BPH; benign prostatic hyperplasia; CNV; copy number variation; CRPC; castration resistant prostate cancer; CTC; circulating tumor cells; ctDNA; cell-free circul
Keywords: ADT; androgen deprivation therapy; AE; adverse event; CRPC; castration-resistant prostate cancer; LHRH; luteinizing hormone-releasing hormone; mCRPC; metastatic CRPC; MFS; metastase-free survival; nmCRPC; non-metastatic CRPC; PFS; progression-free surviva
Keywords: Control arms; mCRPC; Steroids; Prednisolone; Prognosis;
Keywords: prostatic neoplasms; castration-resistant; surveys and questionnaires; case reports; practice patterns; physicians; ADT; androgen deprivation therapy; CME; continuing medical education; CT; computerized tomography; LHRH; luteinizing hormone-releasing horm
Keywords: PC; prostate cancer; mPC; metastatic prostate cancer; ADT; androgen deprivation therapy; CRPC; castration resistant prostate cancer; mCRPC; metastatic CRPC; SNP; single nucleotide polymorphism; CNV; copy number variation; AR; androgen receptor; CTC; circu
Keywords: Aldosterone antagonist; Chronic glucocorticoid toxicity; mCRPC;
Keywords: Abiraterone acetate; mCRPC; Progression-free survival; PSA decline; PSA flare;
Keywords: prostatic neoplasms; immunotherapy; ADT; androgen deprivation therapy; APC; antigen presenting cell; CRPC; castration resistant prostate cancer; GM-CSF; granulocyte-macrophage colony-stimulating factor; mCRPC; metastatic castration resistant prostate canc
27-hydroxycholesterol: A novel player in molecular carcinogenesis of breast and prostate cancer
Keywords: 27-OHC; 27-hydroxycholesterol; ADT; androgen deprivation therapy; AR; androgen receptor; ATF4; Activating Transcription Factor 4; ATF6; Activating Transcription Factor 6; C/EBP; CCAAT / Enhancer binding proteins; CHOP; C/EBP homologous protein; CIP2A; can
Keywords: prostatic neoplasms; castration-resistant; diabetes mellitus; metformin; docetaxel; mortality; ACG; Johns Hopkins Adjusted Clinical Groups; COX-2; cyclooxygenase-2; CRPC; castration resistant PCa; ICES; Institute for Clinical and Evaluative Sciences; mCRP
Keywords: prostatic neoplasms; neoplasm staging; practice guidelines as topic; guideline adherence; ADT; androgen deprivation therapy; APC; advanced prostate cancer; CRPC; castration resistant prostate cancer; EMR; electronic medical record; IUOGP; integrated urolo
Keywords: Adverse event; AR axis-targeted agents; mCRPC; Progression-free survival; Response;
Keywords: ACL; Aceclofenac; AUC; area under the curve; BBB; blood-brain barrier; BCS; Biopharmaceutical classification system; BVC; bupivacaine; CNS; central nervous system; CUR; Curcumin; DMBA; 7,12-dimethylbenzanthracene; DOX; doxorubicin; DSPE-PEG2000; 1,2-diste
Keywords: Docetaxel; Dose Reduction; Efficacy; mCRPC; Toxicity;
Keywords: Prostate cancer; mCRPC; Docetaxel; Prednisolone; Toxicity;
Keywords: mCRPC; Pain control; Patient-reported outcomes; Phase 2 trial; Quality of life; Tyrosine kinase inhibitor
Keywords: Prostate cancer; mCRPC; Sequencing; Combination; Cross-resistance
Keywords: AA; abiraterone acetate; ADT; androgen deprivation therapy; AR; androgen receptor; AR-V; AR splice variant; CRPC; castration-resistant prostate cancer; CTC; circulating tumor cell; CYP; cytochrome P450; FDA; Food and Drug Administration; LBD; ligand-bindi
Keywords: prostatic neoplasms; castration-resistant; ADT; androgen deprivation therapy; AUA; American Urological Association; CRPC; castration resistant prostate cancer; FDA; Food and Drug Administration; mCRPC; metastatic castration resistant prostate cancer; PSA;
Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease
Keywords: PSMA; TGF-β; CD8+ T-cells; Prostate cancer; mCRPC;
Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer
Keywords: AR targeting agents; CHAARTED; mCRPC; mCRPC sequencing; mHSPC;
Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results
Keywords: prostatic neoplasms; prostate-specific antigen; MDV 3100; bone density; drug related side effects and adverse reactions; ADT; androgen deprivation therapy; AE; adverse event; bALP; bone alkaline phosphate; BMD; bone mineral density; CR; complete response;
Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setti
Keywords: AR-targeted therapy; mCRPC; Retrospective; Second-line; Taxane;
A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients
Keywords: 3β-HSD1; 3β-hydroxysteroid dehydrogenase/Î5â4 isomerase 1; CYP17A1; 17αâhydroxylase/17,20âlyase; Î4A; Î4-abiraterone; ABI; abiraterone; ADT; androgen-deprivation therapy; Cmin; mean of trough plasma concentrations measured during the first thr
Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy
Keywords: Immune-based therapy; mCRPC; Prognosis; Provenge; Vaccine;
Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial
Keywords: prostatic neoplasms; neoplasm metastasis; castration; MDV 3100; drug-related side effects and adverse reactions; AE; adverse event; AFFIRM; Study Evaluating the Efficacy and Safety of the Investigational Drug MDV3100; FACT-P; Functional Assessment of Canc
Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer
Keywords: Abiraterone; Chemohterapy-naive; Enzalutamide; mCRPC; Sequential treatment;
Clinical Impact of the Number of Treatment Cycles in First-Line Docetaxel for Patients With Metastatic Castration-Resistant Prostate Cancer
Keywords: Chemotherapy; Dose reductions; Efficacy; mCRPC; Treatment duration;
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials
Keywords: mCRPC; tSRE; rPFS; Abiraterone; Enzalutamide;
CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield
Keywords: mCRPC; metastatic castrate-resistant prostate cancer; PSA; prostate-specific antigen;
Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study
Keywords: chemotherapy; dendritic cells; immunotherapy; mCRPC; prostate cancer;
Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo
Keywords: prostatic neoplasms; castration-resistant; receptors; androgen; prostate-specific antigen; MDV 3100; treatment outcome; ADT; androgen deprivation therapy; AR; androgen receptor; mCRPC; metastatic castration resistant prostate cancer; OS; overall survival;
Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistan
Keywords: Abiraterone acetate; Docetaxel; Enzalutamide; mCRPC; Sequential treatment;
Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer
Keywords: BRCA2; Platinum; Carboplatin; Prostate cancer; mCRPC; DNA repair;
Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial
Keywords: TROPIC; Post hoc analysis; Cabazitaxel chemotherapy; Metastasized castration resistent prostate cancer; Neutropenia predictive; Granulocyte-colony stimulating factor (GCSF); mCRPC;
Original StudyTrial Level Analysis of Prostate-Specific Antigen-Related Versus Unrelated Endpoints in Phase III Trials of First-Line and Second-Line Medical Treatments of Patients With Metastatic Castration-Resistant Prostate Cancer
Keywords: Chemotherapy; Hormonal therapy; mCRPC; Progression-free survival; PSA;
Prostate-Specific Antigen Flare Phenomenon During 223Ra-Dichloride Treatment for Bone Metastatic Castration-Resistant Prostate Cancer: A Case Report
Keywords: Bone metastases; mCRPC; PSA; Radionuclide therapy; Radium-223;
A Whole Blood Assay for AR-V7 and ARv567es in Patients with Prostate Cancer
Keywords: prostatic neoplasms; receptors; androgen; blood; biomarkers; tumor; protein isoforms; AR-FL; full-length androgen receptor; CRPC; castration resistant prostate cancer; CTC; circulating tumor cell; EMT; epithelial-to-mesenchymal transition; EpCAM; epitheli
Original StudySequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices
Keywords: Clinical outcomes; Electronic health record; mCRPC; Retrospective; Treatment sequence;
Abiraterone acetate in metastatic castration-resistant prostate cancer: A retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole
Keywords: Abiraterone; Dosing; Ketoconazole; mCRPC; Response rate;
Safety and Efficacy of Maintenance Therapy With a Nonspecific Cytochrome P17 Inhibitor (CYP17i) After Response/Stabilization to Docetaxel in Metastatic Castration-Resistant Prostate Cancer
Keywords: Cytochrome P17 inhibitor (CYP17i); Docetaxel; Maintenance therapy; mCRPC; Time to progression
Management of Docetaxel Failures in Metastatic Castrate-Resistant Prostate Cancer
Keywords: Sipuleucel-T; Cabazitaxel; Abiraterone; mCRPC;
Integrated Safety Data From 4 Randomized, Double-Blind, Controlled Trials of Autologous Cellular Immunotherapy With Sipuleucel-T in Patients With Prostate Cancer
Keywords: prostate; prostatic neoplasms; sipuleucel-T; immunotherapy; drug toxicity; ADPC; androgen dependent prostate cancer; AE; adverse event; CVE; cerebrovascular event; FDA; Food and Drug Administration; IMPACT; Immunotherapy for Prostate Adenocarcinoma Treatm